Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

03/16/21

BERKELEY HEIGHTS, N.J. , March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced
Read more

PDF Version
Summary Toggle Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference

03/15/21

BERKELEY HEIGHTS, N.J. , March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock

03/12/21

BERKELEY HEIGHTS, N.J. , March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock

03/11/21

BERKELEY HEIGHTS, N.J. , March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer shares of its
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

02/25/21

Conference Call Scheduled February 25, 2021 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell biology,
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results

02/19/21

BERKELEY HEIGHTS, N.J. , Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference

02/10/21

BERKELEY HEIGHTS, N.J. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2021
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

01/11/21

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum , M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures – BERKELEY HEIGHTS, N.J. , Jan.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021

12/30/20

BERKELEY HEIGHTS, N.J. , Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures

12/22/20

- Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - BERKELEY HEIGHTS, N.J. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of Directors

12/21/20

Former CMO & Head of R&D of ArQule joins the Board BERKELEY HEIGHTS, N.J. , Dec. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results

11/11/20

- Conference Call Scheduled November 11, 2020 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter Financial Results

11/05/20

BERKELEY HEIGHTS, N.J. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results
Read more

PDF Version
Summary Toggle Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020

10/26/20

A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib BERKELEY HEIGHTS, N.J. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

10/23/20

BERKELEY HEIGHTS, N.J. , Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum , M.D.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference

10/05/20

BERKELEY HEIGHTS, N.J. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company is scheduled to participate in a
Read more

PDF Version
Summary Toggle Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

09/21/20

BERKELEY HEIGHTS, N.J. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data with
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results

08/12/20

- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

08/05/20

BERKELEY HEIGHTS, N.J. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results on
Read more

PDF Version
Summary Toggle Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

07/13/20

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – -- Data builds on growing body of evidence indicating the promise of dual CDK2/9 inhibition -- BERKELEY
Read more

PDF Version

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter